Powered by
-
NVS Stock Chart
Historical NVS Prices
NOVARTIS SP ADR Stock Analysis
Rating: Sell
Total Grade: D
Analysis Breakdown
| NVS Stock Grade: | D |
| Fundamental Grade: | C |
| Quantitative Grade: | F |
| NVS Earnings | |
| Earnings Growth: | C |
| Earnings Momentum: | D |
| Earnings Surprises: | C |
| Analyst Earnings Revisions: | D |
| NVS Financial Information | |
| Sales Growth: | C |
| Operating Margin Growth: | C |
| Cash Flow: | F |
| Return on Equity: | B |
NOVARTIS SP ADR Stock: Weekly View
| This Week: | D |
|---|---|
| Last Week: | D |
| Two Weeks Ago: | D |
NVS Stock predictions, Articles, and NOVARTIS SP ADR News
- From InvestorPlace
- From the Web
-
FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs - May 18, 2018
The Food and Drug Administration (FDA) announced a list of drug makers that have tried to block generic drugs in its new shame list. Here they are. Continue…
-
Novartis AG (ADR) Stock Drops on Q1 Earnings Miss - April 19, 2018
Novartis (NVS) stock took a hit on Thursday following the release of its earnings report for the first quarter of the year. Continue…
-
5 Biotech IPOs to Watch in April - April 17, 2018
Biotech IPOs happen at a faster rate than most other sectors. Here's a breakdown of the five biotechs going public during April so investors can understand potential investments. Continue…
-
A Big Bet on Gene Therapy Is Just What Novartis AG (ADR) Stock Needs - April 12, 2018
Novartis put its excess cash to good use by broadening its business into the gene therapy market. Competition could prove tough for NVS stock, but Novartis is ready for the challenge ahead. Continue…
-
AveXis Inc Stock Skyrockets on Novartis Deal - April 9, 2018
AveXis (AVXS) stock was flying high to day following news of am $8.7 billion deal that will have Novartis (NVS) acquiring it. Continue…
-
GlaxoSmithKline plc (ADR) Stock Jumps on $13 Billion Novartis Deal - March 27, 2018
GlaxoSmithKline (GSK) stock was up today on news of a $13 billion deal with Novartis (NVS) that it set to close in Summer 2018. Continue…
-
Novartis AG (NVS) a Buy on High-Level Quant Score - December 8, 2017
Novartis AG (NYSE:NVS) is a member of the 134 company Pharmaceuticals GICS industry group, which is part of the 782 company GICS Health Care sector. NVS's market value is $200.3 billion which falls in the top decile in its industry group. Portfolio Grader's current ranking for NVS puts it 15 among the 134 companies in this industry group, giving it a well above-average position; in the top quartile of the sector with a ranking of 109 among the 782 companies in the sector, and number 639 in the nearly 5,000 company Portfolio Grader universe. Continue…
-
Novartis AG (NVS) a Buy on Healthy Quant Score - December 1, 2017
The current recommendation of Buy for Novartis AG (NYSE:NVS) is derived using the Portfolio Grader stock evaluator, which incorporates Louis Navellier's investing methodology. NVS has recently seen its Portfolio Grader rating upgraded from a Hold to a Buy. Continue…
-
3 Stocks to Watch on Friday: Novartis AG (ADR) (NVS), Nutanix Inc (NTNX) and Zumiez Inc. (ZUMZ) - December 1, 2017
Amazon (AMZN) explores online pharmaceuticals with Novartis AG (NVS), Nutanix (NTNX) and Zumiez (ZUMZ) report on their quarterly earnings. Continue…
-
Novartis AG (NVS) a Buy on Solid Earnings Visibility - November 24, 2017
Novartis AG (NYSE:NVS) is classified as a constituent of the 133 company Pharmaceuticals GICS industry group, which is a segment of the 781 company GICS Health Care sector. NVS has a market value of $195.5 billion which is in the top 10% of its industry group. Currently, the stock's Portfolio Grader ranking places it 23 among the 133 companies in this industry group, putting in the top quartile; in the top quartile of the sector with a ranking of 166 among the 781 companies in the sector, and number 1,096 in the nearly 5,000 company Portfolio Grader universe. Continue…
